Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters

Epidemiol Infect. 2019 Oct 24;147:e295. doi: 10.1017/S095026881900181X.

Abstract

Conditions and evidence continue to evolve related to the prediction of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters, which affect assumptions related to forecasting risks and evaluating potential risk management options. Multiple recent reviews provided information about individual iVDPV excreters, but inconsistencies among the reviews raise some challenges. This analysis revisits the available evidence related to iVDPV excreters and provides updated model estimates that can support future risk management decisions. The results suggest that the prevalence of iVDPV excreters remains highly uncertain and variable, but generally confirms the importance of managing the risks associated with iVDPV excreters throughout the polio endgame in the context of successful cessation of all oral poliovirus vaccine use.

Keywords: Polio; polio vaccine virus; virology (human) and epidemiology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Female
  • Global Health
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Deficiency Syndromes / drug therapy
  • Immunologic Deficiency Syndromes / epidemiology
  • Immunologic Deficiency Syndromes / virology*
  • Immunologic Factors / therapeutic use
  • Male
  • Models, Immunological
  • Poliomyelitis / drug therapy
  • Poliomyelitis / prevention & control*
  • Poliomyelitis / transmission
  • Poliomyelitis / virology
  • Poliovirus Vaccines*
  • Prevalence
  • Public Health Surveillance
  • Risk Assessment
  • Virus Shedding*

Substances

  • Antiviral Agents
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Poliovirus Vaccines